[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"HaEmek Medical Center, Israel\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":187},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,42,66,94,117,140,163],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100495512","phase-2-preliminary-effectiveness-of-individual-and-group-mdma-assisted-therapy-for-israeli-veterans-with-ptsd-and-moral-injury-100495512",false,"NCT05732155","Preliminary Effectiveness of Individual and Group MDMA-assisted Therapy for Israeli Veterans With PTSD and Moral Injury.","Preliminary Effectiveness of Individual and Group MDMA-assisted Therapy for Israeli Veterans With PTSD and Moral Injury From Special Forces Undercover Units","Inclusion Criteria:\n\n* Are veterans of special forces undercover units in the Israeli army.\n* Are fluent in speaking and reading the predominantly used or recognized language of the study site (Hebrew).\n* Are able to swallow pills.\n* Agree to have study visits recorded, including Experimental Sessions, and non-drug psychotherapy sessions.\n* Must provide a contact (relative, spouse, close friend, or other support person) who is willing and able to be reached by the investigators in the event of a participant becoming suicidal or unreachable.\n* Must agree to inform the investigators within 48 hours of any medical conditions and procedures.\n* Agree to the following lifestyle modifications : comply with requirements for fasting and refraining from certain medications prior to Experimental Sessions, not participate in any other interventional clinical trials during the duration of the study, remain overnight at the study site after each Experimental Session and be driven home after, and commit to medication dosing, therapy, and study procedures.\n* At Screening, meet DSM-5 criteria for current PTSD with a symptom duration of 6 months or longer.\n* At Screening, have at least moderate PTSD symptoms in the last month, based on PCL-5 total score of 36 or greater.\n* May have well-controlled hypertension.\n* May have asymptomatic Hepatitis C virus (HCV).\n* May have alcohol or substance use disorder.\n* May have a history of or current Diabetes Mellitus (Type 2).\n* May have hypothyroidism if taking adequate and stable thyroid replacement medication.\n* May have a history of, or current, glaucoma if approval for study participation is received from an ophthalmologist.\n\nExclusion Criteria:\n\n* Are not able to give adequate informed consent.\n* Have used Ecstasy (material represented as containing MDMA) more than 10 times within the last 10 years or at least once within 6 months of the first Experimental Session; or have previously participated in a MAPS-sponsored MDMA clinical trial.\n* Have any current problem which, in the opinion of the investigator or study physician, might interfere with participation.\n* Sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the sponsor-investigator or study clinician, contraindicates participation in the study.\n* Have received Electroconvulsive Therapy (ECT) within 12 weeks of enrollment.\n* Have a history of or a current primary psychotic disorder.\n* Have a current eating disorder with active purging assessed via MINI and clinical interview.\n* Have current major depressive disorder with psychotic features assessed via MINI.\n* Have a current alcohol or substance use disorder other than caffeine or nicotine that the investigators, therapy team, and\u002For study physician judge to be a safety concern for enrollment in the study.\n* Have an active illicit (other than cannabis) or prescription drug substance use disorder at any severity within 12 months prior to enrollment.\n* Have current Personality Disorders.\n* .Any participant presenting current serious suicide risk,\n* Require ongoing concomitant therapy with a psychiatric medication with exceptions described in protocol section on Concomitant Medications.\n* Have a history of any medical condition that could make receiving a sympathomimetic drug harmful because of increases in blood pressure and heart rate.\n* Have uncontrolled essential hypertension using the standard criteria of the American Heart Association (values of 140\u002F90 milligrams of Mercury \\[mmHg\\] or higher assessed on three separate occasions).\n* Have a history of ventricular arrhythmia at any time, other than premature ventricular contractions (PVCs) in the absence of ischemic heart disease.\n* Have Wolff-Parkinson-White syndrome or any other accessory pathway that has not been successfully eliminated by ablation.\n* Have a history of arrhythmia, other than premature atrial contractions (PACs) or occasional PVCs in the absence of ischemic heart disease, within 12 months of screening.\n* Have a marked Baseline prolongation of QT\u002FQTc interval . QTc interval \\> 450 milliseconds (ms) in males and \\>460 ms in females corrected using Fridericia's formula.\n* Have a history of additional risk factors for Torsade de pointes (e.g., heart failure, hypokalemia, family history of Long QT Syndrome).\n* Require use of concomitant medications that prolong the QT\u002FQTc interval during Experimental Sessions.\n* Have symptomatic liver disease or have significant liver enzyme elevations.\n* Have history of hyponatremia or hyperthermia.\n* Weigh less than 48 kilograms (kg).\n* Have engaged in ketamine-assisted therapy or used ketamine within 12 weeks of enrollment.","ALL","18 Years",{"count":19,"type":20},60,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","The overall objective of this study is to use standard clinical measures to explore the safety and preliminary effectiveness of open-label MDMA-assisted therapy with a flexible dose of methylenedioxymethamphetaminel, in participants with Post traumatic Stress Disorder and moral injury, in individual and group treatment settings.\n\nThe overall safety objective is to assess the severity, incidence, and frequency of AEs, AEs of Special Interest (AESIs), and Serious Adverse Events (SAEs), concomitant medication use, suicidal ideation and behavior and vital signs .",[26,27,28],"Post Traumatic Stress Disorder","Moral Injury","MDMA ('Ecstasy')","RECRUITING","2026-07-07",{"date":32,"type":33},"2026-07-08","ACTUAL",{"date":35,"type":33},"2023-06-01",{"date":37,"type":20},"2028-12-01",{"name":39,"class":40},"HaEmek Medical Center, Israel","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":49,"minAge":17,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":21,"phases":53,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":41},"100577876","phase-4-induction-of-labor---comparison-propess-with-prostaglandin-e2-vaginal-gel-and-balloon-catheter-100577876","NCT06803992","Induction of Labor - Comparison Propess With Prostaglandin E2 Vaginal Gel and Balloon Catheter","Induction of Labor in Women With Unfavorable Cervix at Term - Comparison of Propess Versus Prostaglandin E2 Vaginal Gel and Extra-amniotic Balloon Catheter","Inclusion Criteria:\n\n* Pregnant women at term (37 weeks of gestation or more) with singleton\n* pregnancies that are intended for IOL.\n* Initial bishop score \\\u003C5\n* No contraindications to receive either treatment.\n* Women who will give informed consent to be included in the study.\n* Women at or over the age of 18.\n\nExclusion Criteria:\n\n* Women with a known hypersensitivity or contraindications to Propess \u002F PGE2.\n* Parity 5 or more\n* Labor contractions more than 4 in 20 min\n* Glaucoma\n* History of previous uterine surgery\n* Hypersensitivity to prostaglandins\n* Vaginal delivery is contraindicated\n* Active cardiac, renal, pulmonary, or hepatic disease\n* Severe asthma or pulmonary disease","FEMALE","60 Years",{"count":52,"type":20},140,[54],"PHASE4","One of every four births in the Western world is induced, usually due to the risk of maternal and fetal morbidity. There are several methods of labor induction, pharmacological and mechanical. In cases of unfavorable cervix (Bishop score is below 5), cervical ripening can be induced by either prostaglandins E2 (slow release 10 mg dinoprostone insert (propess) or vaginal gel 1-2 mg) or mechanically by Foley catheter balloon (FCB).\n\nThe efficacy of labor induction of propess versus vaginal gel combined with FCB was not studied previously.\n\nThe goal of this randomized controlled trial is to compare the efficacy of propess versus PGE2 vaginal gel combined with FCB in women with singletons undergoing labor induction at term. The main question it aims to answer is to compare the time from the beginning of labor induction until delivery.",[57],"Induction of Labor","2025-11-24",{"date":60,"type":33},"2025-12-01",{"date":62,"type":33},"2025-04-06",{"date":64,"type":20},"2027-01-29",{"name":39,"class":40},{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":49,"minAge":4,"maxAge":4,"enrollmentInfo":73,"targetDuration":4,"studyType":21,"phases":75,"briefSummary":76,"conditions":77,"keywords":79,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":41},"100592191","phase-4-comparing-high-versus-low-dose-of-oxytocin-in-gravida-women-with-bmi-30-and-above-which-are-undergoing-induction-of-labor-100592191","NCT06990217","Comparing High Versus Low Dose of Oxytocin, in Gravida Women With BMI 30 and Above Which Are Undergoing Induction of Labor","Comparison of Oxytocin Dosing Regimen' Low Versus High, in Gravida Women With BMI 30 and Above Undergoing Induction of Labor","Inclusion Criteria:\n\n* Women at term (37-42 weeks), requiring the use of oxytocin for induction of labor or for augmentation of labor.\n* BMI 30 and above\n* Viable singleton pregnancies\n* Cephalic presentation.\n* No contraindication for vaginal delivery\n\nExclusion Criteria:\n\n* Women with previous cesarean delivery\n* Multiple pregnancy\n* Multiple fetal malformations\n* IUFD",{"count":74,"type":20},130,[54],"The goal of this clinical trial is to compare between higher and lower dose of oxytocin to induce delivery in obese women. Researches will compare between low and high doses of oxytocin. the study group will use high dose of oxytocin (20 units in 1000 ml) versus the control group which will use low dose of oxytocin (10 units of oxytocin in 1000 ml)",[57,78],"Augmentation of Labor",[80,81,82,83,84],"induction of labor","augmentation of labor","obese","obese gravida","high dose of oxytocin in obese gravida","NOT_YET_RECRUITING","2025-05-17",{"date":88,"type":33},"2025-05-25",{"date":90,"type":20},"2025-06",{"date":92,"type":20},"2027-12",{"name":39,"class":40},{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":49,"minAge":17,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":21,"phases":103,"briefSummary":105,"conditions":106,"keywords":4,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":41},"100566523","hysteroscopic-intrauterine-suturing-100566523","NCT06656286","Hysteroscopic Intrauterine Suturing","Hysteroscopic Intrauterine Suturing by Using X-Tack - Pilot Study","Inclusion Criteria:\n\n* Benign indication for hysterectomy\n\nExclusion Criteria:\n\n* Evidence or suspicious for malignancy",{"count":102,"type":20},2,[104],"NA","Clinical trial The aim of the study is to evaluate the safety and feasibility of intrauterine suturing with Apollos X-tack, inserted into the uterus by hysteroscope.\n\nPrimary outcome:\n\nIntrauterine suture will sustain the procedure - when the uterus will be opened the suture will be observed.\n\nSecondary outcome:\n\nProcedure complications. Study Design Interventional pilot Study\n\nStudy group:\n\nWomen undergoing laparoscopic hysterectomy.",[107,108],"Niche","Uterine Disease","2025-03-12",{"date":111,"type":33},"2025-03-13",{"date":113,"type":20},"2025-04-25",{"date":115,"type":20},"2026-07-02",{"name":39,"class":40},{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":121,"acronym":4,"eligibilityCriteria":122,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":123,"enrollmentInfo":124,"targetDuration":4,"studyType":21,"phases":126,"briefSummary":127,"conditions":128,"keywords":130,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":4},"100557765","trans-canal-tympanoplasty-with-local-anesthesia-using-fat-graft-and-tachosil-100557765","NCT06542367","Trans Canal Tympanoplasty With Local Anesthesia Using Fat Graft and \"TachoSil\"","Inclusion Criteria:\n\n* Chronic tympanic membrane perforation (\\>6 months).\n* Central tympanic membrane perforation.\n* Air bone gar of 35 dB or lower at the operated ear.\n* No active otorrhea in the operated ear in the preceding 3 month prior to the procedure.\n* No evidence of a retraction pocket and no suspicion for a cholesteatoma.\n\nExclusion Criteria:\n\n* Known ossicular chain dysfunction\n* The tympanic membrane perforation edges are not accessible\u002Fvisualized transcanal\n* Pregnancy\n* Allergy to lidocaine","99 Years",{"count":125,"type":20},20,[104],"Eligible participants with chronic tympanic membrane perforation (\\>6 month) will be given a detailed description and offered to participate in the study.\n\nthe study investigates the efficacy of trans canal tympanoplasty with local anesthesia using fat pad and \"Tachosil\". Participants will be followed for 1 year after the procedure with otological examination and successive hearing evaluations.",[129],"Tympanic Membrane Perforation",[131],"Tympanoplasty","2024-08-12",{"date":134,"type":33},"2024-08-13",{"date":136,"type":20},"2024-09-01",{"date":138,"type":20},"2026-09-01",{"name":39,"class":40},{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":4,"eligibilityCriteria":146,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":147,"enrollmentInfo":148,"targetDuration":4,"studyType":21,"phases":150,"briefSummary":151,"conditions":152,"keywords":4,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":4},"100536372","comparison-of-the-efficacy-of-transcranial-direct-current-stimulation-tdcs-of-the-primary-motor-cortex-m1-or-the-prefrontal-cortex-combined-with-aerobic-activity-for-alleviation-of-fibromyalgia-symptoms-100536372","NCT06263972","Comparison of the Efficacy of Transcranial Direct Current Stimulation (tDCS) of the Primary Motor Cortex (M1) or the Prefrontal Cortex Combined With Aerobic Activity for Alleviation of Fibromyalgia Symptoms.","Comparison of the Efficacy of Transcranial Direct Current Stimulation (tDCS) of the Primary Motor Cortex (M1) or the Prefrontal Cortex Combined With Aerobic Activity for Alleviation of Fibromyalgia Symptoms and on Improving Self-Regulation and Quality of Life- a Randomized, Double Blinded Controlled Prospective Study","Inclusion Criteria:\n\n* Diagnosed Fibromyalgia\n* Pain scale level of 4 or higher\n* Fail to achieve adequate pain relief with Fibromyalgia treatments\n* stable Fibromyalgia treatment for at least 4 weeks.\n* Ability to perform aerobic exercise\n\nExclusion Criteria:\n\n* Other Causes of pain\n* Psychotic disorder\n* Severe Depression\n* Cognitive disorder\n* Drug or alcohol abuse in the last 6 months\n* pregnancy","65 Years",{"count":149,"type":20},120,[104],"The goal of this study is to demonstrate the effectiveness of treating fibromyalgia using combination of electrical stimulation with aerobic activity.\n\nParticipants will be randomly assigned to stimulation in a ratio of 1:1:1. 120 participants (40 in each group). The therapeutic course will include moderate aerobic physical activity (at 60% of the target heart rate adjusted for age) 3 times a week for 4 weeks (a week of adjustment, and 3 weeks of treatment), along with low current electrical stimulation for 3 weeks.",[153,154],"Fibromyalgia","Electric Shock","2024-02-14",{"date":157,"type":33},"2024-02-16",{"date":159,"type":20},"2024-03",{"date":161,"type":20},"2026-07",{"name":39,"class":40},{"id":164,"slug":165,"hasResults":11,"nctId":166,"briefTitle":167,"officialTitle":167,"acronym":4,"eligibilityCriteria":168,"healthyVolunteers":169,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":170,"targetDuration":4,"studyType":21,"phases":171,"briefSummary":172,"conditions":173,"keywords":4,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":4},"100464041","meniers-disease---bone-density-study-100464041","NCT05322538","Menier's Disease - Bone Density Study","Inclusion Criteria:\n\n* Definite Meniere's disease\n\nExclusion Criteria:\n\n* hyperthyroidism\n* hyperparathyroidism\n* acromegaly\n* hypogonadism\n* diabetes melitus\n* chronic renal failure\n* alcoholism\n* cushing syndrome\n* rheumatoid arthritis\n* systemic lupus erythematosus\n* ankylosing spondylitis\n* inflammatory bowel disease\n* obstructive lung disease\n* sarcoidosis\n* amyloidosis\n* celiac disease.\n* chronic treatment with bisphosphonates\n* chronic treatment with glucocorticoids\n* chronic treatment with androgen deprivation therapy\n* chronic treatment with gonadotropin releasing hormone agonist chronic treatment with aromatase inhibitor chronic treatment with loop diuretics chronic treatment with proton pump inhibitors chronic treatment with anti-seizure drugs chronic treatment with warfarin chronic treatment with SSRI chronic treatment with alpha or beta-blockers",true,{"count":19,"type":20},[104],"Meniere's disease is a progressive and debilitating inner ear disease characterised by vertigo and hearing loss. Several studies have linked Menierws disease with lower bone density and lower vitamin D levels. In the current prospective study definite Meniere's patients will be followed over a period of 2 year, during which repetitive measurements of bone density, vitamin D plasma levels, blood pressure as well as hearing and vestibular tests will be made. Results will be compared to healthy controls.",[174,175,176,177,178],"Meniere Disease","Osteoporosis","Osteopenia","Vitamin D Deficiency","Vestibular Disorder","2022-08-02",{"date":181,"type":33},"2022-08-03",{"date":183,"type":20},"2022-10-01",{"date":185,"type":20},"2028-12-31",{"name":39,"class":40},""]